Browse by ["viewname_eprint_publisher" not defined]

H

Herrlinger, Ulrich and Tzaridis, Theophilos and Mack, Frederic and Steinbach, Joachim Peter and Schlegel, Uwe and Sabel, Michael and Hau, Peter and Kortmann, Rolf-Dieter and Krex, Dietmar and Grauer, Oliver and Goldbrunner, Roland and Schnell, Oliver and Baehr, Oliver and Uhl, Martin and Seidel, Clemens and Tabatabai, Ghazaleh and Kowalski, Thomas and Ringel, Florian and Schmidt-Graf, Friederike and Suchorska, Bogdana and Brehmer, Stefanie and Weyerbrock, Astrid and Renovanz, Miriam and Bullinger, Lars and Galldiks, Norbert and Vajkoczy, Peter and Misch, Martin and Vatter, Hartmut and Stuplich, Moritz and Schaefer, Niklas and Kebir, Sied and Weller, Johannes and Schaub, Christina and Stummer, Walter and Tonn, Joerg-Christian and Simon, Matthias and Keil, Vera C. and Nelles, Michael and Urbach, Horst and Coenen, Martin and Wick, Wolfgang and Weller, Michael and Fimmers, Rolf and Schmid, Matthias and Hattingen, Elke and Pietsch, Torsten and Coch, Christoph and Glas, Martin (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. LANCET, 393 (10172). pp. 678-688. ISSN 0140-6736, 1474-547X